The Nifty Bank index closed 0.37 per cent up at 41298.35.

For the quarter ended June 30, 2022, the company has reported a consolidated total income of Rs 2377 crore, up 8.69 per cent from last quarter total income of Rs 2187 crore and up 9.34 per cent from last year same quarter total income of Rs 2174 crore.

The transaction will see the exit of existing investors of Curatio, such as ChrysCapital (which holds a 20% stake) and Sequoia Capital (33%). Promoters, including GK Ramani, and the management will also be exiting the company.

The drug firm had reported a net loss of Rs 11 crore in the April-June period of last fiscal.

The drug firm had reported a net loss of Rs 11 crore in the April-June period of last fiscal.Total income for the period under review stood at Rs 317 crore as compared with Rs 314 crore in the year-ago period, Unichem Laboratories said in a regulatory filing.

"At Torrent Power, Aman was involved at a challenging point in the business journey and was instrumental in bringing about a customer orientation transformation within the distribution business and also made noteworthy contributions in enhancing efficiency in operations," the company said.

"Further, he has led several organic growth initiatives that have started delivering market share gains, with a focus on new product launches. Aman is a key contributor in the evaluation of acquisition opportunities and driving the strategic direction of India business," the company said.

The company last month had received Abbreviated New Drug Application approval from the US Food and Drug Administration (USFDA) for Aripiprazole tablets USP; a development that had sent its share price soaring.

Drug firm Unichem Laboratories on Saturday reported a consolidated net loss of Rs 11.48 crore for the quarter ended on June 30, 2021. The company had posted a net profit of Rs 2.43 crore for the corresponding period of the previous fiscal, Unichem Labs said in a regulatory filing.

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

The share touched a 52-week high of Rs 332.40 and a 52-week low of Rs 75.10 on 08 February 2021 and 24 March 2020, respectively.

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

The company has received abbreviated new drug application (ANDA) approval to market its Zonisamide capsules, USP 25 mg, 50 mg and 100 mg from the United States Food and Drug Administration (USFDA), Unichem Laboratories said in a BSE filing.

The company has received abbreviated new drug application (ANDA) approval to market its Zonisamide capsules, USP 25 mg, 50 mg and 100 mg from the United States Food and Drug Administration (USFDA), Unichem Laboratories said in a BSE filing.

The company has received abbreviated new drug application (ANDA) approval for its Celecoxib capsules in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (USFDA), Unichem said in a filing to BSE.

The company has received abbreviated new drug application (ANDA) approval for its Celecoxib capsules in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (USFDA), Unichem said in a filing to BSE.

The share touched its 52-week high Rs 304.20 and 52-week low Rs 75.10 on 04 August, 2020 and 24 March, 2020, respectively.

‘We have a buy on Dr Reddys and Lupin. Dr Reddys definitely has a positive but the valuation remains very challenging after this recent run up of Rs 1,000 or more.

Sharing information with shareholders in company's annual report for 2019-20, the drug firm said the ongoing coronavirus pandemic calls for concentrated efforts to build upon capacities for active pharmaceutical ingredients (APIs) in the country.

Drug firm Unichem Laboratories on Wednesday said it has received approval from the US health regulator for its Amiodarone tablets used to treat irregular heartbeat. The approved product is a generic version of Wyeth Pharmaceuticals Inc's Cordarone tablets.